Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| VAG0532-50 | 7 days | 50 µg | $800.00 |
Select product before adding to cart
|
||
| VAG0532-100 | 7 days | 100 µg | $1,200.00 | |||
| VAG0532-1 | 7 days | 1 mg | $4,800.00 |
Product Overview | |
| Name | HBsAg G145R |
|---|---|
| Description | |
| Hepatitis B Surface Antigen G145R Recombinant | |
| Introduction | |
| HCV is a small 50nm, enveloped, single-stranded, positive sense RNA virus in the family Flaviviridae. HCV has a high rate of replication with approximately one trillion particles produced each day in an infected individual. Due to lack of proofreading by the HCV RNA polymerase, the HCV has an exceptionally high mutation rate, a factor that may help it elude the host's immune response. Hepatitis C virus is classified into six genotypes (1-6) with several subtypes within each genotype. The preponderance and distribution of HCV genotypes varies globally. Genotype is clinically important in determining potential response to interferon-based therapy and the required duration of such therapy. Genotypes 1 and 4 are less responsive to interferon-based treatment than are the other genotypes (2, 3, 5 and 6). | |
| Source | |
| Escherichia Coli. | |
| Physical Appearance | |
| Sterile filtered colorless solution. | |
| Formulation | |
| Both Conjugate protein (Core-NS3-NS4-NS5 ) and Capture protein (Core-NS3-NS4-NS5 + HCV core are in PBS. | |
| Stability | |
| Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles. | |
| Purity | |
| Greater than 95.0% as determined by SDS-PAGE. | |
| Precautions | |
| HBsAg G145R is for research use only and not for use in diagnostic or therapeutic procedures. | |
Background |
The surface antigen of the virus, HBsAg, is a crucial marker for both infection diagnosis and vaccination efficacy. However, the emergence of HBsAg mutant proteins, characterized by specific variations in the viral genome, poses a substantial challenge to accurate diagnostics, treatment, and prevention strategies. This research delves into the realm of HBsAg mutant proteins, exploring their genetic diversity, clinical relevance, and impact on disease management. Genetic Diversity of HBsAg Mutants: HBsAg mutants are HBV variants that exhibit specific amino acid substitutions within the major hydrophilic region (MHR) of the HBsAg protein. These mutations can arise due to the selective pressure from the host immune response or antiviral therapies. Understanding the genetic diversity of these mutants is essential for tracking the evolution of HBV and developing effective diagnostic assays and vaccines. Clinical Relevance and Diagnostic Challenges: HBsAg mutants present significant challenges in clinical diagnosis. Traditional HBsAg assays may fail to detect these mutants, leading to false-negative results. This diagnostic hurdle can delay appropriate medical interventions and affect disease management. Furthermore, individuals infected with HBsAg mutants might have altered disease progression, complicating the prediction of disease outcomes and treatment responses. Implications for Vaccination Programs: The emergence of HBsAg mutants also raises concerns regarding the effectiveness of vaccination programs. Mutations within the HBsAg protein might result in vaccine escape variants, reducing the efficacy of existing vaccines. This scenario necessitates continuous surveillance and the development of next-generation vaccines that target a broader spectrum of HBV mutants. Understanding the interplay between viral evolution and vaccine-induced immunity is crucial for ensuring the long-term success of vaccination strategies. Therapeutic Challenges and Future Prospects: In the context of antiviral therapies, HBsAg mutants can pose challenges in treatment efficacy. These mutants might exhibit resistance to certain antiviral drugs, impacting the choice of therapeutic regimens. Research efforts are underway to identify novel drug targets and develop antiviral agents that can effectively combat HBsAg mutants. Additionally, advancements in gene therapy and immunomodulatory approaches hold promise for future therapeutic interventions. The study of HBsAg mutant proteins represents a vital area of research in the field of virology and hepatology. Understanding the genetic diversity, clinical implications, and therapeutic challenges associated with these mutants is essential for devising comprehensive strategies for HBV diagnosis, prevention, and treatment. As we delve deeper into the complexities of HBsAg variants, we pave the way for more accurate diagnostics, effective vaccines, and targeted therapies, ultimately contributing to the global efforts to combat hepatitis B and its associated complications. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
